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CV events and T2DM. CONCLUSIONS: Orlistat is a cost-effective treatment to aid
weight reduction in primary care when using a threshold of £20,000 per QALY.
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OBJECTIVES: As part of a medico-economic study on a fibrin sealant used in ortho-
pedic surgery to decrease allogeneic transfusion requirement, this study was con-
ducted to evaluate the overall cost of transfusion from hospital perspective.
METHODS:A multicenter prospective study was carried out from March 14, 2011 to
June 1, 2011 in orthopedic surgery wards of 3 French university hospitals. A micro-
costing has been developed to identify global costs of transfusion through: the
acquisition cost of red blood cell (RBC), supplies used for a transfusion, and times
spent by medical and nurse staff for the management of the transfusion timed by
a pharmacy resident with a stopwatch. Corresponding costs for staff were esti-
mated from mean salaries for medical and non medical staff in 2011.RESULTS: Five
transfusions were observed in each site. A physician spent 1’01” 43” (mean 
standard deviation) for the prescription of RBC. Personal care assistants and hos-
pital workers brought samples to the Blood Bank (BB), transmitted the document to
the BB, and delivered RBC to the ward which took 10’17” 05’46” and 10’47” 03’20”
respectively. Nurses spent 52’23” 04’39” for the control of the documents, the
ultimate pre-transfusion control at patient’s bedside, the administration of RBC
and the monitoring of the transfusion. No adverse event occurred during the study.
The mean global cost of the transfusion of a RBC was estimated at 254 Euros.
Regarding global cost, management of transfusion was estimated at 31 Euros rep-
resenting 12% of the overall cost of transfusion. CONCLUSIONS: The study shows
the heavy workload represented by each transfusion for a nurse in the context of
shortage of nurses. These results may be helpful to fill a pharmacoeconomic model
used to estimate the incremental cost effective of using fibrin sealant in orthopedic
surgery.
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OBJECTIVES: Evaluate the relative impact of migraine-related outcomes using gen-
eralized healthy-time equivalences (HTE). METHODS: A best-practice conjoint
analysis or discrete-choice experiment (DCE) evaluated migraine-related outcomes
reported in the Completeness of Response Survey (CORS). We elicited patients’
trade-off preferences for migraine symptoms with different clinically relevant du-
rations, including symptom-free time. Preference-parameter estimates were used
to determine the amount of symptom-free time that was utility-equivalent to 24-
hour migraine episode profiles described by acute headache, post-headache, and
symptom-free phases. These HTEs quantify the impact of migraine-related out-
comes using a fully general utility-theoretic conceptual framework. Unlike quality-
adjusted life years (QALYs), HTEs do not require assuming that utility of a brief, but
severe, outcome is a simple fraction of a quality-adjusted year. Also unlike QALYs,
HTEs do not require risk neutrality, and easily account for personal characteristics
that may determine preferences for health outcomes. RESULTS: A total of 539
people with a self-reported physician diagnosis of migraine completed the survey.
As expected, migraineurs were negatively affected by the duration of headache-
phase and post-headache-phase symptoms. However, for some groups in the sam-
ple we found no statistical difference in relative preferences for different pain
severities in the acute headache phase. Subjects had clear preferences for different
levels of daily-activity limitations experienced during the post-headache phase.
Results also showed that subjects in the sample were averse to risk. We also found
preference heterogeneity based on individual characteristics. CONCLUSIONS: This
study demonstrates the feasibility of obtaining standardized healthy-time equiv-
alences derived from clinically-relevant symptom-duration tradeoff data as a fea-
sible alternative to QALYs for acute, self-limiting conditions. The results also sug-
gest that the assumptions associated with the use of conventional QALYs are not
met by our sample of migraineurs; adding to the mounting body of evidence that
encourages the use of more flexible utility-theoretic measures of quality-adjusted
time.
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OBJECTIVES: Previous studies have examined the humanistic burden of rheuma-
toid arthritis; however, less research has been conducted to understand the factors
that are most strongly associated with the health-related quality of life of these
patients. METHODS: Data from the European 2010 National Health and Wellness
Survey (an annual survey of respondents from France, Germany, Italy, Spain, and
the UK) were used in the current study. Only respondents who reported being
diagnosed with RA (N498) were included in the analyses. Health state utilities
(SF-6D), derived from the SF-12, were examined on a bivariate level across a variety
of subgroups (e.g., years diagnosed, treatment status, comorbidities, joints af-
fected, etc). Health state utilities were also predicted from demographic and pa-
tient characteristic information using multiple regressions. RESULTS:A total of 498
patients (0.86%) reported being diagnosed with RA. These patients were mostly
female (64.3%) and had an average age of 52.3 years. Most patients were diagnosed
with RA for more than 10 years (55.8%). Several demographic and patient charac-
teristic factors were significantly associated with health state utilities. RA patients
in Spain (Adjusted Mean0.60) and Italy (Adjusted mean0.53) had the highest and
lowest, respectively, utility scores. Severe RA (Adjusted mean0.51), comorbid
Crohn’s disease (Adjusted mean0.52), and RA affecting the spine (Adjusted
mean0.54) were associated with the largest decrements in utility scores (all
ps.05). CONCLUSIONS: Although previous studies have documented the burden
of RA in Europe, the current study suggests that burden is not uniform. Certain
geographies, particularly Italy, are associated with a greater burden for patients
with RA. Similarly, patient characteristics, such as arthritis of the spine and comor-
bid Crohn’s disease, have a large effect on the quality of life of these patients. These
results suggest a more comprehensive assessment of patient characteristics is
necessary to fully capture the quality of life burden of RA.
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OBJECTIVES: To analyze QoL of patients with chronic pain due to osteoarthritis of
the knee (OA) or low back pain (LBP) using the EQ-5D questionnaire in phase III
trials with tapentadol prolonged release (PR) and oxycodone controlled release
(CR).METHODS: Three phase III trials in OA and LBP with the same design included
the EQ-5D questionnaire to measure utilities of patients with chronic pain treated
with either tapentadol PR, oxycodone CR or placebo. Utilities were obtained at
baseline and endpoint (15 weeks). An analysis was performed to explore how
EQ-5D distinguished among various health states. RESULTS: Mean utility of all
patients treated with tapentadol PR (N978) increased from 0.42 at baseline to 0.60
at endpoint, and for patients treated with oxycodone CR (N998) from 0.43 at
baseline to 0.56 at endpoint, and for patients treated with placebo (N990) from
0.41 at baseline to 0.55 at endpoint. The increase in utility was significantly higher
(p0.001) in patients treated with tapentadol compared to those treated with oxy-
codone or placebo. Presence and severity of adverse events, as well as insufficient
pain relief substantially decreased utility values in both tapentadol and oxycodone
treatment groups. Whereas the highest utilities were seen in the groups of patients
who had30% pain improvement and patients who tolerated the treatment (0.69-
0.72), patients who withdrew due to an adverse event or due to lack of efficacy had
much lower utilities (0.40-0.51). CONCLUSIONS: EQ-5D utilities of OA and LBP pa-
tients increased significantly compared to baseline when treated with tapentadol
PR or oxycodone CR, whereby the increase was significantly higher with tapentadol
PR. Sufficient pain relief and reduction of severe treatment-related adverse events
resulted in a large beneficial impact on EQ-5D utility values. This analysis clearly
demonstrates that the EQ-5D is a useful tool to measure QoL in pain studies.
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OBJECTIVES: Compare health measurements of females with bleeding disorders
(FBD) to males with von Willebrand disease (VWD) and females in the general
population (FGP). METHODS: Subjects 12yrs of age, with VWD and FBD in the
Canadian national registry were eligible for assessment. Health status and health-
related quality of life (HRQL) were measured using the Health Utilities Index Mark
3 (HUI3). The results were compared with normative data by age and gender from
the 2002/3 Joint Canada / United States Survey of Health and from the 1991 Cana-
dian General Social Survey. Mean differences and proportions were assessed using
t-test and chi square, respectively. Differences 0.05 in mean HRQL scores and
10% for proportions were considered important. Statistical significance was set at
p0.05. RESULTS: 411 HUI3 assessments were analyzed. Among 20-79 year old
FBD, mean HRQL scores were lower (diff0.150; p0.05) than in FGP. For those45
years, FBD had lower HRQL scores (diff0.080; p0.027) than males with VWD. No
difference between males with VWD and FBD 45 years of age was observed
(p0.871). Excellent health was self-reported by 18.4% of females from the registry
compared to 22.7% (p0.05) of FGP and 29.9% (p0.02) of males with VWD. Between
FDB and FGP important differences (p0.001) in the proportion reporting disability
were observed for HUI3 attributes vision, emotion, cognition, and pain for those
45 years, and ambulation, dexterity, emotion and pain for those 45 years. Be-
tween FBD and males with VWD an important difference (p0.005) in the propor-
tion reporting disability was observed for pain. FBD have similar HRQL (0.72) to
moderate (0.73) and severe (0.71) HIV-negative haemophiliacs. CONCLUSIONS: Fe-
males with bleeding disorders have greater morbidity than females in the general
population or males with VWD.
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OBJECTIVES: Chronic pain is a common and universal phenomenon that appears
at all ages and in all populations. It has a substantially impact on the quality of
patients’ daily life as well as their physical and mental function. The objective of
this study was to document attributes of a pain medication that are relevant from
the perspective of patients with chronic pain. METHODS: In a first step literature
review, focus groups with patients and one to one interviews with highly accepted
experts in the field of indication were conducted to identify relevant treatment
attributes of a pain medication. A pretest was conducted to verify the structure of
relevant and dominant attributes using factor analysis and choosing the most
frequent mentioned representative of each factor. The discrete choice experiment
(DCE) itself used a self administered survey including sociodemographics and an
indication specific parameter (pain). For statistical data analysis of the DCE, a ran-
dom effect logit model was used and coefficients were presented. RESULTS: In a
first step we detected 36 attributes. Factor analysis revealed seven remaining at-
tributes. A total of N1324 German patients participated in the self administered
survey, resulting in the following ranking of relevant attributes for treatment de-
cision: “no character change”, “less nausea and vomiting”, “pain reduction” (Coef-
ficient:  0.9 for all attributes, “high impact”); “rapid effect”, “less danger of addic-
tion” (Coefficient  0.5, “middle impact”); “applicability with comorbidity”
(Coefficient: 0.3), “improvement of quality of sleep” (Coefficient 0.25). All attri-
butes were highly significant (p  0.001). CONCLUSIONS: Due to the subjective
nature of pain, the management of chronic pain needs to be patient centered.
Therefore an understanding of patient preferences is essential for inclusion in
treatment decisions. In summary, DCE and direct assessment proved to be valid
instruments to elicit treatment preferences in chronic pain treatment.
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OBJECTIVES: The TRIM-Weight is a Patient-Reported Outcome (PRO) questionnaire
designed to assess the efficacy and tolerability of weight loss medication. The
objective of this study was to produce translations into number of languages that
are conceptually equivalent to the original and to other language versions, ensur-
ing the validity of the translations within the target cultures. METHODS: The stan-
dard linguistic validation methodology was followed: two forward translations
with reconciliation, two back translations and review, developer review, cognitive
interviews with five obese people for each language, and proof reading. RESULTS:
Numerous cultural and linguistic issues became apparent throughout the transla-
tion process, including the following: The term for ‘craving’ proved difficult to
translate into Spanish, Italian, French (France) and French (Canada). The develop-
er’s input and cognitive debriefing interviews were used to find appropriate termi-
nology to convey the intended meaning. For example, it had to be specified in
French (France) that this related to one particular food; ’Jitteriness’ was mentioned
in the scale as a physical side-effect of the drug; this word was problematic in
Dutch (where the translator had to use a term related to ‘trembling’), and Brazilian
Portuguese (where the translator used a term related to being physically anxious
and unable to relax); Brazilian respondents had difficulty understanding that they
must respond only concerning prescription weight loss medication and the related
instruction had to be underlined to clarify this; several vocabulary problems oc-
curred, e.g. finding terms for ‘isolated’ in Russian, ‘embarrassment’ in Brazilian
Portuguese and ‘weight loss plateaus’ in Austria German. Each issue was discussed
until a suitable alternative was found which could be tested in cognitive interviews
with patients. CONCLUSIONS: The TRIM-Weight questionnaire was translated and
linguistically validated using a rigorous translation process. A number of cultural
and linguistic issues became apparent and were resolved. TRIM-Weight is now
validated for use in multinational trials.
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WITH PATIENT DEMOGRAPHICS AND MEASURES OF OBESITY
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OBJECTIVES: As the incidence of obesity continues to rise, there is pressure to find
and evaluate new weight loss interventions; understanding the impact of obesity
and weight loss on patients is an invaluable part of this process. We aimed to
examine associations among patient characteristics, self-reported depression, vi-
tality and the obesity and weight-loss quality-of-life (OWL-QOL) instruments in a
population of overweight and obese patients. METHODS: We analysed baseline
data from a clinical trial involving patients with body mass index (BMI) between
27–45kg/m2. Data included: patient demographics; obesity measures including
BMI, weight and body composition; responses to the OWL-QOL questionnaire; re-
sponses to the Patient Health Questionnaire (PHQ), assessing depression; and re-
sponses to the SF-36 vitality subscale. Least angle regression (LAR) was used to
select the most relevant obesity measures to include in multivariable regression
models. Univariate associations were examined using Spearman’s correlations.
RESULTS: Baseline data were available for 341 patients with a mean age of 44.2
(SD10.7) years, mean BMI of 35.2 (SD4.67) kg/m2, and mean OWL-QOL total score
of 55.3 (SD24.2). 83.3% were female. LAR showed that among obesity measures,
percentage of total fat was most significantly associated with the OWL-QOL total
score. Based on Spearman’s correlations, the OWL-QOL total score was signifi-
cantly correlated with gender (
0.233, p0.001), total fat (
-0.264, p0.001), PHQ
(
-0.138, p0.035), and vitality (
0.456, p0.001). In the final model (R20.34),
vitality (0.55, p0.001), female gender (-8.71, p0.026) and race/ethnicity
(12.3, African American versus Other, 1.08 White versus Other; p0.002 for
both comparisons), but not percentage of total fat, were significantly associated
with the OWL-QOL total score. CONCLUSIONS: The OWL-QOL was significantly
associated with gender, race/ethnicity and vitality. Importantly, based on LAR,
percentage of total fat was more significantly associated with the OWL-QOL total
score than other obesity measures, including BMI.
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OBJECTIVES: A previous survey distributed in Europe and the US found that lupus
affects patients’ career, physical well-being and everyday living. The LEO survey
was developed to explore further the effect of lupus on work productivity, fatigue
and health-related quality of life (HRQoL) in Europe. METHODS: The survey had
four sections. Section 1 included patient-developed questions on demographics,
lupus diagnosis and impact of lupus on work and career. Sections 2–4 used lupus-
specific patient-reported outcomes (PRO) instruments to assess work impairment
(Work Productivity and Activity Impairment Questionnaire, Lupus V2.0), fatigue
(lupus-specific Fatigue Severity Scale) and HRQoL (LupusQoL). The survey was
available May–August 2010 and in five European languages. RESULTS: A total of
1566 participants with self-reported lupus completed the survey: from France
(n139), Germany (n537), Italy (n357), Spain (n267) and the UK (n266). Most
were female (93%, 1440/1557) and aged 26–55 years (81%, 1253/1550). In section 1,
over two-thirds (70%, 1028/1475) of participants reported that lupus affected their
career (highest UK, 79% [199/252]; lowest France, 56% [73/131]). Of these, 31% (288/
928) now work flexible hours, 29% (265/928) applied for sick leave, 24% (219/928)
applied for social or disability allowance and 17% (156/928) changed career. Of
those who reduced work hours, almost a quarter (23%, 150/646) had to reduce by
75%. In the WPAI assessment, participants reported missing an average of 13%
(SD24.2) of their working time because of lupus. At work, productivity was re-
duced by an average of 40% (SD25.8). Overall, an average of 43% (SD27.1) of total
work hours available to participants were lost due to lupus. Ability to carry out
non-work activities such as housekeeping, childcare and studying was, on average,
impaired by 56% (SD26.7). CONCLUSIONS: Lupus diminishes European patients’
likelihood of working and their productivity while at work. These findings empha-
sise the need for improved management of lupus.
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OBJECTIVES: Comparative studies between Euroqol-5D (EQ-5D) and Short-form 6D
(SF-6D) utilities have been performed for a number of diseases, but not for patients
with Pompe disease. Pompe disease is a rare disease (prevalence of 5/10,000).
Characteristic features of late onset Pompe disease are impaired ambulatory and
respiratory functioning. We compared the psychometric properties of EQ-5D and
SF-6D in these patients and assessed the convergent validity and the ability of the
instruments to discriminate with respect to functional capabilities and subjective
health.METHODS: EQ-5D utilities were calculated using the Dutch value set. EQ-5D
and SF-6D domains and utilities were compared by correlation coefficients and
descriptive statistics. We assessed whether EQ-5D and SF-6D were able to discrim-
inate between different levels of Pompe disease severity as defined by subjective
health status (SF36 rating scale and Visual Analogue Scale (VAS) divided into ter-
tiles) and functional capabilities (use of wheelchair and respiratory support).
RESULTS: Eighty-two patients (82% of the total Dutch Pompe population) com-
pleted both EQ-5D and SF-6D (average follow-up 3.8 observations; 3.1 years). Cor-
relations between theoretically related domains were highly significant and mod-
erately strong (range rho0.392 – rho0.632). The SF-6D domain “vitality” had no
EQ-5D counterpart. Utility values were comparable (mean EQ-5D  0.739; mean
SF-6D 0.710), and moderately correlated (r0.544). Discriminative properties of
EQ-5D and SF-6D were comparable; patients using wheelchair, or respiratory sup-
port and patients with a lower VAS score reported lower EQ-5D and SF-6D utilities.
CONCLUSIONS: The descriptive system of the SF-6D described Pompe disease
more accurate. Discriminative properties of EQ-5D and SF-6D outcomes were sim-
ilar in this population.
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EVALUATING THE CROSS-OVER EFFECT ON HEALTH-RELATED QUALITY OF
LIFE IN A RANDOMIZED CROSS-OVER STUDY OF HEMOPHILIA-A PATIENTS
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OBJECTIVES: To investigate the cross-over effects on health-related quality of life
(HRQoL) in an randomized cross-over design study for hemophilia-A patients.
METHODS: HRQoL via SF-36 Health Survey was measured every 3 months in a
prospective, randomized, cross-over, investigator-initiated study comparing 6
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